Perspective Therapeutics, Inc.
About Perspective Therapeutics, Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2018
- $5.9M
- Net income
- -$103.1M
- Total assets
- $267.0M
- Market cap
- $345.6M
- Operating margin
- -6250.8%
- Net margin
- -5596.7%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $1.5M
- Operating expenses
- $92.3M
- Operating income
- -$90.9M
- Income tax
- -$2.1M
- Net income
- -$81.4M
- EPS (basic)
- $-1.23
- EPS (diluted)
- $-1.23
Balance sheet
- Total assets
- $341.1M
- Current assets
- $231.2M
- Total liabilities
- $50.4M
- Current liabilities
- $18.2M
- Shareholders’ equity
- $290.7M
Cash flow
- Operating cash flow
- -$18.3M
- Investing cash flow
- -$218.9M
- Financing cash flow
- $289.4M
- Net cash flow
- $52.2M
Statements via Polygon.io (SEC filings)
- Market cap
- $345.6M
- EPS (diluted)
- $-1.23
- Shares outstanding
- 117.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 29, 2003
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $103.1M in FY2018.
- Revenue grew 1% from FY2023 to FY2024.
- Trading 48% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Perspective Therapeutics, Inc..
Write a review
News about Perspective Therapeutics, Inc.
News & sentiment via Polygon.io
